Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,636.36
(
2.00%
)
US TECH 100
23,770.40
(
2.10%
)
Dow Jones
46,585.22
(
2.21%
)
Brent Oil
95.75
(
-11.45%
)
Bitcoin
70,901.38
(
4.52%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 160457

Thursday, 07/25/2013 7:12:27 PM

Thursday, July 25, 2013 7:12:27 PM

Post# of 257269
GILD expects GT3 labeling to be the focus of Sofosbuvir's FDA advisory panel on 10/25/13, according to today's CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today